| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1056/NEJM198702193160807 |
| P698 | PubMed publication ID | 3543680 |
| P2093 | author name string | Mason JW | |
| P433 | issue | 8 | |
| P921 | main subject | amiodarone | Q410061 |
| P304 | page(s) | 455-466 | |
| P577 | publication date | 1987-02-01 | |
| P1433 | published in | The New England Journal of Medicine | Q582728 |
| P1476 | title | Amiodarone | |
| P478 | volume | 316 |
| Q42028893 | A Mechanistic Study on the Amiodarone-Induced Pulmonary Toxicity |
| Q92154740 | A Stretchable and Flexible Cardiac Tissue-Electronics Hybrid Enabling Multiple Drug Release, Sensing, and Stimulation |
| Q23918231 | A characterization of amiodarone-induced pulmonary toxicity in F344 rats and identification of surfactant protein-D as a potential biomarker for the development of the toxicity |
| Q40745450 | A consensus report on antiarrhythmic drug use. |
| Q43585474 | Accumulation of amiodarone and desethylamiodarone by rat alveolar macrophages in cell culture |
| Q70254134 | Acute hepatitis after a loading dose of intravenous amiodarone |
| Q45083261 | Acute pulmonary inflammation in hamsters following intratracheal administration of amiodarone |
| Q33409837 | Acute thrombocytopenia in patients treated with amiodarone is caused by antibodies specific for platelet membrane glycoproteins |
| Q37623943 | Advances in molecular biology. Potential impact on diagnosis and treatment of disorders of the thyroid |
| Q28325574 | Adverse drug reactions leading to hospital admission |
| Q64247668 | Aggravation of atrial arrhythmia by amiodarone during the perinatal period: A case report |
| Q42550733 | Akinesia and amiodarone therapy |
| Q53964397 | Ambulatory cardiac monitoring for the evaluation of antiarrhythmic agents. |
| Q28069857 | Amiodaron in atrial fibrillation: post coronary artery bypass graft |
| Q42163862 | Amiodarone Inhibits Trypanosoma cruzi Infection and Promotes Cardiac Cell Recovery with Gap Junction and Cytoskeleton Reassembly In Vitro |
| Q44594365 | Amiodarone Rescue Therapy for Severe Decompensated Heart Failure Initially Unsuitable for β-Blockers |
| Q36832205 | Amiodarone Therapy Guided by Electrophysiologic Testing: An Update |
| Q42277569 | Amiodarone and torsades de pointes in patients with advanced heart failure |
| Q77360278 | Amiodarone causes endothelium-dependent vasodilation in human hand veins in vivo |
| Q31601523 | Amiodarone has exclusively non-genomic action on cardiac beta-adrenoceptor regulation. |
| Q69737532 | Amiodarone hepatotoxicity: prevalence and clinicopathologic correlations among 104 patients |
| Q36660391 | Amiodarone in Long Term Prophylaxis |
| Q39631851 | Amiodarone in the management of cardiac arrhythmias: current concepts |
| Q42116063 | Amiodarone induced acute interstitial pneumonitis |
| Q68469412 | Amiodarone pulmonary toxicity: Prospective evaluation of serial pulmonary function tests |
| Q42192972 | Amiodarone toxicity presenting as pulmonary mass and peripheral neuropathy: the continuing diagnostic challenge |
| Q77425816 | Amiodarone-induced disruption of hamster lung and liver mitochondrial function: lack of association with thiobarbituric acid-reactive substance production |
| Q68505269 | Amiodarone-induced hepatic phospholipidosis: A morphological alteration independent of pseudoalcoholic liver disease |
| Q69237879 | Amiodarone-induced pulmonary toxicity in the rat |
| Q37771879 | Amiodarone-induced pulmonary toxicity: an under-recognized and severe adverse effect? |
| Q55002733 | Amiodarone-induced reversible and irreversible hepatotoxicity: two case reports. |
| Q90953371 | Amiodarone-induced thyrotoxicosis in heart failure with a reduced ejection fraction: A retrospective cohort study |
| Q35313411 | Amiodarone. An overview of its pharmacological properties, and review of its therapeutic use in cardiac arrhythmias |
| Q33777249 | Amiodarone: ionic and cellular mechanisms of action of the most promising class III agent |
| Q35373386 | An open label, randomised, crossover study comparing sotalol and atenolol in the treatment of symptomatic paroxysmal atrial fibrillation. |
| Q34562300 | Anesthesia-related cardiac arrest in children. An update |
| Q28360102 | Antagonism of thyroid hormone action by amiodarone in rat pituitary tumor cells |
| Q41089628 | Antiarrhythmic actions of amiodarone: a profile of a paradoxical agent |
| Q34973496 | Antiarrhythmic agents and the risk of malignant neoplasm of liver and intrahepatic bile ducts |
| Q40392117 | Antiarrhythmic agents in older patients. Current state of knowledge |
| Q30469749 | Antiarrhythmic drug therapy in the treatment of atrial fibrillation. |
| Q72364104 | Antiarrhythmic drugs and polyneuropathy. The Collaborative Group for the Study of Polyneuropathy |
| Q35028892 | Antiarrhythmic effect and its underlying ionic mechanism of 17beta-estradiol in cardiac myocytes |
| Q91738098 | Atrial Fibrillation Post Coronary Artery Graft Surgery: A Review Of Literature |
| Q56607936 | Atrial fibrillation |
| Q33827902 | Atrial fibrillation after cardiac operation: risks, mechanisms, and treatment |
| Q42561319 | Block of cardiac sodium channels by amiodarone studied by using Vmax of action potential in single ventricular myocytes |
| Q44806589 | Bronchiolitis obliterans organizing pneumonia and amiodarone: spontaneous resolution |
| Q57780462 | Bronquiolitis obliterante con neumonía organizativa focal y amiodarona |
| Q36619090 | Cancer metastasis and EGFR signaling is suppressed by amiodarone-induced versican V2. |
| Q41639191 | Cardiac potassium currents and channels. Part II: Implications for clinical practice and therapy |
| Q67926700 | Characterization of sarcoplasmic reticulum in skinned heart muscle cultures |
| Q72017495 | Cibenzoline Versus Flecainide in the Prevention of Paroxysmal Atrial Arrhythmias: A Double‐Blind Randomized Study |
| Q36264153 | Clinical chemistry of anti-arrhythmic drugs |
| Q47679630 | Combination therapy with carvedilol and amiodarone in patients with severe heart failure |
| Q36723528 | Combined anti-arrhythmic therapy with class 1 and class 3 drugs |
| Q58739485 | Comedication with interacting drugs predisposes amiodarone users in cardiac and surgical intensive care units to acute liver injury: A retrospective analysis |
| Q42910758 | Comparison of the Length of Hospital Stay between the Patients with Atrial Fibrillation Treated with Amiodarone and Patients with Normal Sinus Rhythm after Coronary Artery Bypass Graft. |
| Q74589348 | Con: All patients should not receive pharmacologic prophylaxis for atrial fibrillation after cardiac surgery |
| Q44955642 | Continuous spinal anaesthesia for abdominal surgery in a patient receiving amiodarone |
| Q30437633 | Current therapy for supraventricular tachycardia |
| Q41733355 | Current treatment recommendations in antiarrhythmic therapy |
| Q68859985 | Cytotoxic interactions of cardioactive cationic amphiphilic compounds in primary rat hepatocytes in culture |
| Q48107970 | DNA damage-induced apoptosis and mitogen-activated protein kinase pathway contribute to the toxicity of dronedarone in hepatic cells. |
| Q44921438 | Detection of amiodarone pulmonary toxicity: To screen or not to screen, that is the question! |
| Q35888038 | Differences in hepatic drug accumulation and enzyme induction after chronic amiodarone feeding of two rat strains: role of the hydroxylator phenotype? |
| Q40490665 | Drug effects on the electrocardiogram. A review of their clinical importance |
| Q33940871 | Drug therapy of sustained ventricular tachyarrhythmias. Is there still a role? |
| Q69503992 | Drug-induced liver disease |
| Q44444652 | Effect of amiodarone on the descending limb of the T wave. |
| Q73574876 | Effectiveness of amiodarone as a single oral dose for recent-onset atrial fibrillation |
| Q67908767 | Effects of Amiodarone on Serum T3and T4Concentrations in Hyperthyroid Patients Treated with Propylthiouracil |
| Q72074940 | Effects of Antiarrhythmic Drugs on Epicardial Defibrillation Energy Requirements and the Rate of Defibrillator Discharges |
| Q92604420 | Effects of N-acetyl cysteine, vitamin E and vitamin C on liver glutathione levels following amiodarone treatment in rats |
| Q46668919 | Effects of amiodarone on ouabain binding to microsomal Na+, K(+)-ATPase in guinea-pig heart preparations |
| Q35887696 | Effects of antiarrhythmic agents classified as class III group on ischaemia-induced myocardial damage in canine hearts |
| Q35871237 | Effects of long-term oral administration of amiodarone on the electromechanical performance of rabbit ventricular muscle |
| Q52375028 | Effects of surfactants on amiodarone intestinal absorption. I. Sodium laurylsulfate. |
| Q72079642 | Efficacy and Safety of Combination Therapy with Amiodarone and Type I Agents for Treatment of Inducible Ventricular Tachycardia |
| Q52663514 | Efficacy and Safety of Low-Dose Amiodarone Therapy for Tachyarrhythmia in Congenital Heart Disease. |
| Q42536446 | Efficacy and safety of carvedilol in patients with chronic heart failure receiving concomitant amiodarone therapy. Australia/New Zealand Heart Failure Research Collaborative Group |
| Q68503190 | Efficacy and safety of intravenous amiodarone in acute refractory arrhythmias |
| Q58854963 | Efficacy and safety of sotalol versus quinidine for the maintenance of sinus rhythm after conversion of atrial fibrillation |
| Q68498136 | Elevation of serum total cholesterol and triglyceride levels during amiodarone therapy |
| Q92954289 | Generation of Human iPSC-Derived Intestinal Epithelial Cell Monolayers by CDX2 Transduction |
| Q37809218 | Group XV phospholipase A₂, a lysosomal phospholipase A₂. |
| Q90092939 | Handling of Ventricular Fibrillation in the Emergency Setting |
| Q34329882 | Hemokinins and endokinins |
| Q44966723 | High-dosage continuous amiodarone therapy to treat new-onset supraventricular tachyarrhythmias in surgical intensive care patients: an observational study |
| Q36492134 | Hypertrophic cardiomyopathy: Prognosis with medical or surgical therapy |
| Q41737284 | Impact of structural heart disease on the selection of class III antiarrhythmics for the prevention of atrial fibrillation and flutter |
| Q36964943 | Interaction with the hERG channel and cytotoxicity of amiodarone and amiodarone analogues |
| Q23918223 | Intratracheal amiodarone administration to F344 rats directly damages lung airway and parenchymal cells |
| Q41459856 | Intravenous amiodarone |
| Q45115921 | Intravenous amiodarone for ventricular arrhythmias: overview and clinical use. |
| Q28608404 | Liver cirrhosis induced by long-term administration of a daily low dose of amiodarone: a case report |
| Q73213127 | Long-term low-dose amiodarone therapy in the management of ventricular and supraventricular tachyarrhythmias: efficacy and safety |
| Q73550857 | Low-dose amiodarone-related complications after cardiac operations |
| Q37928845 | Mechanical and electrical complications of acute myocardial infarction |
| Q42471056 | Modulation of Calmodulin Properties by Amiodarone and its Major Metabolite Desethylamiodarone |
| Q44794491 | N-nitrosylation potential of mono-N-desethylamiodarone at physiological pH. |
| Q40681386 | New antiarrhythmic drugs in pediatric use: amiodarone |
| Q68128750 | Newer antiarrhythmic drugs |
| Q40913079 | Newer concepts in the medical management of patients with congestive heart failure. |
| Q68385522 | Oral amiodarone loading therapy. I. The effect on serial signal-averaged electrocardiographic recordings and the QTc in patients with ventricular tachyarrhythmias |
| Q36186137 | P450-Based Drug-Drug Interactions of Amiodarone and its Metabolites: Diversity of Inhibitory Mechanisms |
| Q74292358 | Part 10: pediatric advanced life support. European Resuscitation Council |
| Q74026579 | Pathology of intrinsic cardiac neurons from ischemic human hearts |
| Q41113143 | Perioperative management of drug therapy, clinical considerations |
| Q40877835 | Pharmacologic therapy in patients with ventricular tachyarrhythmias. |
| Q69933440 | Pharmacologic treatment of hypertrophic cardiomyopathy: beta-blockade or calcium blockade or what? |
| Q44372485 | Pharmacological cardioversion of recent onset atrial fibrillation with intravenous amiodarone in patients receiving long-term amiodarone therapy: is it reasonable? |
| Q36838560 | Pharmacotherapy in Medicare beneficiaries with atrial fibrillation |
| Q37791349 | Pharmacotherapy of Atrial Fibrillation: A Pathophysiological Perspective and Review |
| Q34418185 | Plasma protein binding of amiodarone in a patient population: measurement by erythrocyte partitioning and a novel glass-binding method |
| Q38684267 | Potassium and Sodium Transport in Yeast |
| Q37119654 | Potent synergistic in vitro interaction between nonantimicrobial membrane-active compounds and itraconazole against clinical isolates of Aspergillus fumigatus resistant to itraconazole |
| Q75201197 | Prevention of atrial fibrillation after cardiac valvular surgery by epicardial, biatrial synchronous pacing |
| Q67997994 | Proceedings of the British Pharmacological Society, Clinical Pharmacology Section. Ireland, 6-8 July, 1988. Abstracts |
| Q41146146 | Pulmonary complications after long term amiodarone treatment |
| Q34048472 | Recent progress in advanced cardiac life support |
| Q71796672 | Recurrent amiodarone lung toxicity after withdrawal of the drug and treatment with corticoids |
| Q37781460 | Reversibility of blue-gray cutaneous discoloration from amiodarone |
| Q33613107 | Safety of antiarrhythmic drugs in children |
| Q24680017 | Selective inhibition of K+ -stimulation of Na,K-ATPase by bretylium |
| Q73334767 | Synthesis and class III type antiarrhythmic activity of 4-aroyl (and aryl)-l-aralkylpiperazines |
| Q43204853 | The effects of plasmapheresis on thyroid hormone and plasma drug concentrations in amiodarone-induced thyrotoxicosis |
| Q79987911 | The influence of hyperlipoproteinemia on in vitro distribution of amiodarone and desethylamiodarone in human and rat plasma |
| Q57389792 | The mallory body: Morphological, clinical and experimental studies (part 1 of a literature survey) |
| Q30462759 | The reversal of amiodarone-induced perioperative reduction in cardiac systolic reserve in dogs |
| Q53290011 | The role of CYP3A4 in amiodarone-associated toxicity on HepG2 cells |
| Q41630489 | The side effect profile of class III antiarrhythmic drugs: focus on d,l-sotalol |
| Q70244867 | Toxic myopathies |
| Q43787170 | Toxicity of amiodarone and amiodarone analogues on isolated rat liver mitochondria |
| Q36038058 | Ultrastructural Changes in Rat's Atrial Cardiomyocytes After Short Term Administration of Amiodarone and Possible Protective Role of Vitamin E. |
| Q71458783 | Ultrastructural evidence of thyroid damage in amiodarone-induced thyrotoxicosis |
| Q77468071 | Unexpected instant death following successful coronary artery bypass graft surgery (and other clinical settings): atrial fibrillation, quinidine, procainamide, et cetera, and instant death |
| Q42726456 | Unilateral subarachnoid block for ankle arthrodesis in patient on long term amiodarone therapy |
| Q34516598 | Update in pediatric resuscitation |
| Q42215095 | Use of intravenous amiodarone for emergency treatment of life-threatening ventricular arrhythmias |
| Q68136729 | Ventricular arrhythmias |
| Q33144673 | Ventricular arrhythmias in congestive heart failure: clinical significance and management |
| Q38708541 | Ventricular tachycardia. |
| Q37509103 | Warfarin-amiodarone drug-drug interactions: determination of [I](u)/K(I,u) for amiodarone and its plasma metabolites |
| Q41893328 | Zinc-gold cooperative catalysis for the direct alkynylation of benzofurans. |
| Q68086624 | [Changes in myocardial metabolism induced by drugs used during intensive care] |
| Q52597049 | [Clinical aspects of treatment with amiodarone]. |
| Q87146961 | [Medical therapy of heart and lung diseases. Effects on the respective other organ] |
| Q73656203 | [Practice guidelines of the Spanish Society of Cardiology on cardiac arrythmias] |
| Q73474837 | [Pulmonary toxicity caused by drugs] |
| Q80577085 | [Treatment of patients with ventricular preexcitation] |
Search more.